Compare UFCS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFCS | GERN |
|---|---|---|
| Founded | 1946 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.4M | 808.3M |
| IPO Year | 1995 | N/A |
| Metric | UFCS | GERN |
|---|---|---|
| Price | $44.22 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $40.50 | $2.17 |
| AVG Volume (30 Days) | 107.8K | ★ 13.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,386,412,000.00 | N/A |
| Revenue This Year | $11.80 | $26.91 |
| Revenue Next Year | $8.77 | $43.75 |
| P/E Ratio | $38.63 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $25.81 | $1.04 |
| 52 Week High | $49.94 | $2.01 |
| Indicator | UFCS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 34.40 |
| Support Level | $36.27 | $1.22 |
| Resistance Level | $49.94 | $1.29 |
| Average True Range (ATR) | 1.46 | 0.06 |
| MACD | -0.67 | -0.00 |
| Stochastic Oscillator | 0.87 | 21.15 |
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.